Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing.

Journal of medical genetics - 1 Aug 2022

Wang Yifan, Golesworthy Bryn, Cuggia Adeline, Domecq Celine, Chaudhury Prosanto, Barkun Jeffrey, Metrakos Peter, Asselah Jamil, Bouganim Nathaniel, Gao Zu-Hua, Chong George, Foulkes William D, Zogopoulos George

Abstract excerpt

BACKGROUND: Traditional medical genetics models are unable to meet the growing demand for germline genetic testing (GT) in patients with exocrine pancreatic cancer (PC). This study investigates the impact of an ambulatory oncology clinic-based GT model. METHODS: From 2012 to 2021, patients with PC were prospectively enrolled and considered for GT. Two chronological cohorts were compared: (1) the preuniversal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Predisposition to Disease
Share to Genetic Testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germ Cells

Share to Germ-Line Mutation

Share to Neuroendocrine Tumor Research Advances

Share to Pancreatic and Hepatic Oncology Research

Share to Pancreatic Neoplasms

Share to Thyroid Cancer Diagnosis and Treatment

Source

Identifiers

PMID: 34556502
DOI: 10.1136/jmedgenet-2021-108054

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing.PMID 34556502Read ↗

Mainstream and fast-track genetic testing in pancreatic cancer patients and its impact on treatment: our experience in a tertiary hospital in Spain.Semantic proximity Read ↗

Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center Oncology Clinic.Semantic proximity Read ↗

Germline genetic testing among patients with pancreatic adenocarcinoma: A Pancreatic Cancer Action Network patient survey.Semantic proximity Read ↗

Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment.Semantic proximity Read ↗

Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study.Semantic proximity Read ↗

Development of a Novel Protocol for Germline Testing in Pancreatic Cancer.Semantic proximity Read ↗

Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake.Semantic proximity Read ↗

Genomic testing for pancreatic cancer in clinical practice as real-world evidenceSemantic proximity Read ↗

Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer.Semantic proximity Read ↗

Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer.Semantic proximity Read ↗

Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study.Semantic proximity Read ↗

Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.